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ABSTRACT
Immunohistochemistry remains the overwhelming technique of choice for test 
biomarker evaluation in both clinical or research settings when using formalin-
fixed, paraffin embedded tissue sections.  However, validations can be complex with 
significant issues about specificity, sensitivity and reproducibility.  The vast array of 
commercially available antibodies from many vendors may also lead to non-standard 
approaches which are difficult to cross-reference.  In contrast mRNA detection, by in 
situ hybridization (ISH) with sequence specific probes, offers a realistic alternative, 
with less validation steps and more stringent and reproducible assessment criteria.  
In the present study mRNA ISH was evaluated in prospectively and retrospectively 
collected FFPE samples within a cancer biobank setting.  Three positive control probes, 
POLR2A, PPIB and UBC were applied to FFPE sections from a range of tumour types 
in FFPE whole-face (prospective collection) or TMA (retrospective collection) formats 
and evaluated semi-quantitatively and by image analysis.  Results indicate that mRNA 
can be robustly evaluated by ISH in prospectively and retrospectively collected tissue 
samples.  Furthermore, for 2 important test biomarkers, PD-L1 and c-MET, we show 
that mRNA ISH is a technology that can be applied with confidence in the majority 
of tissue samples because there are quantifiable levels of control probes indicating 
overall mRNA integrity.
INTRODUCTION
Detection of mRNA in formalin-fixed, paraffin 
embedded (FFPE) tissue samples by chromogenic RNA in 
situ technology has become a reliable alternative for a wide 
range of biomarkers in many areas of research including 
cancer and neurosciences [1-3]. However, the quality of 
FFPE samples retrieved from storage archives following 
routine pathology management pathways which may have 
relatively wide variations in fixation times compared to 
prospectively targeted biobank collections has not been 
fully established. Indeed there are contradictory opinions 
about the quality and quantity of nucleic acids that can be 
extracted from such FFPE collections and their potential 
use in downstream analysis [4].
RNAscope® Technology provided by, Advanced 
Cell Diagnostics (ACD) is a very sensitive in situ 
hybridization technology. Based on ACD’s unique 
patented probe design strategy which enables 
simultaneous signal amplification and background noise 
suppression, RNAscope technology represents one of 
the most significant advances in ISH technology in over 
40 years and there is clear evidence of the promise of 
RNAscope technology to address many of the biological 
or pathological challenges currently faced by scientists, 
such as biomarker interpretation in tissue, quantitation and 
heterogeneity of expression [5-7]. 
In general, immunohistochemical (IHC) assays may 
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be inefficient with a lack of high quality antibodies for 
many newly discovered biomarker targets, coupled to 
extensive validation times and inconsistent performance. 
RNAscope is therefore highly attractive but must be 
suitable for detection of mRNA in multiple FFPE tissue 
samples with simple validation protocols. Furthermore, 
the technology should be robust enough to take account of 
acceptable variations in fixation parameters (time before 
fixation, time of fixation, time before dissection of gross 
resection specimen to optimal block size) which may 
present in large numbers of routine samples within a study 
cohort. This was demonstrated recently by a review of the 
challenges and pitfalls in detecting PD-L1 expression in 
lung cancer, by IHC [6]. Comparison of PD-L1 expression 
in different NSCLC clinical trials showed a high variation 
in PD-L1 prevalence. This variation can potentially be 
explained by differences in patient demographic, therapies 
and by variation in quality of assay antibodies or IHC 
methods used for detection. Alternative methods like 
RNAscope® ISH have been tested to complement IHC 
analysis and it has been suggested that “mRNA ISH may 
identify patients that would benefit from immunotherapy 
that would otherwise be negative  for PD-L1 protein 
expression by IHC” [6].
The purpose of the present study was twofold: 
Firstly, to assess, using 3 RNAscope control probes 
(POL2RA, PPIB and UBC), the suitability of RNAscope 
in four tumour types (colorectal, breast, prostate and 
ovarian) whereby FFPE tissue had been prospectively 
collected from patients consented to the Northern 
Ireland Biobank (NIB); secondly to assess the mid-
range control probe PPIB expression and correlate to test 
probe biomarkers (PD-L1 and c-MET) in a series of 353 
colorectal cancer (CRC) FFPE samples collected over 
a 5-year period within routine pathology practice in the 
Belfast Health and Social Care Trust (BHSCT). These 
samples were available within tissue microarray (TMA) 
format.
RESULTS
Prospectively collected FFPE samples – 
assessment of whole-face sections
On initial microscopic evaluation the 4 tumour 
types showed uniform expression levels of the RNAscope 
control probes POLR2A, PPIB and UBC across the entire 
surface area of all tissue sections. Examples of expression 
in the tumour types are shown in Figure 1. In general 
probe expression was stronger in tumour epithelial cells 
Figure 1: Examples of control probe expression in FFPE tissues from a prospectively collected cohort of samples. (A 
and D) POLR2A, (B and E) PPIB, (C and F) UBC. A, B and C are examples from colorectal tissue, D, E and F are examples from ovarian 
tissue. Note the increasing expression level from POLR2A to UBC.
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Figure 2: Quantitative expression by Spotstudio image analysis of three control probes in 6 cancer samples from 4 
different tumour types. (A). Region of tumour and stroma in a colorectal cancer case showing high expression of PPIB. (B). Example 
of the ROI selections for spot studio analysis in both tumour (red) and stroma (blue) compartments. Note the increased expression of PPIB 
in the tumour cells compared to stroma. (C) Graphed results are presented as average # spots estimated per cell in both tumour and stromal 
compartments. In all cases the horizontal red line depicts the lower threshold of expected expression. In almost all tumour compartments 
the expression of control probes would determine the tissues as fit-for-purpose for test biomarker analysis. Cut offs in stromal compartments 
are less robust. 
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than in surrounding regions of stroma (lymphoid or 
fibroblast cells). No expression of the negative control 
probe bacterial DapB was observed in any of the tissue 
samples. 
Quantification of POLR2A, PPIB and UBC was 
performed using Spotstudio software in 6 distinct regions 
of interest (ROI), 3 from tumour and 3 from stromal 
compartment of each tissue block (see Figure 2A & 2B). 
Results are expressed as average number of spots per cell 
and are displayed as a box-and-whisker plot (min, max) 
with medians indicated by the horizontal bar (Figure 2C). 
This analysis confirmed the quality of the tumour tissue 
samples for mRNA analyses by In Situ Hybridization. For 
POLR2A, the lowest expressing control probe, all but two 
tumour regions (1 ovarian, 1 prostate) had at least 2 spots 
per cell and in many ROIs were much higher. 
Similarly, for PPIB and UBC control probes, most 
tumour regions had an average number of spots per cell 
well within expected guidelines. The average number of 
spots per cell for PPIB was >8 in all but 1 case from each 
cohort. In all tumour compartments UBC probe expression 
was >15 spots-per-cell. 
Expression of all three control probes was lower 
in cells in regions of stromal tissue compared to tumour 
Figure 3: Boxplots depicting the average number of spots per cell of PPIB at three levels in four regions of interest 
(ROI). Prostate (A), breast (B), ovarian (C) and colorectal cancer (D). While variations are observed all ROIs irrespective of depth into the 
block would be suitable for test probe analysis. Table of descriptive statistics (E) summarising the mean, standard deviation and standard 
error between each level for the four ROIs.
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regions (Figure 2C). For POLR2A most cells had at least 1 
spot-per-cell. The range of PPIB expression in stroma was 
quite variable but in most cases was above 3 spots per-cell. 
UBC expression was generally high in stromal regions of 
tumour with a low of 6.29 in a single ovarian cancer case. 
From each tumour type a single example was 
selected for analysis of PPIB expression through the 
depth of the block at intervals of 100 microns. Four ROIs 
in the tumour compartment of each block were analysed 
at each of the 3 levels. Differences in expression levels 
were seen between the different ROIs across the tumour 
but reasonably consistent expression of PPIB was present 
at each of the three levels through the block (Figure 3). 
The most marked differences was observed in ROI 3 in 
ovarian tissue but the level with lowest expression would 
still be seen as fit-for-purpose for test probe analyses. 
The relatively low SDs and SEs suggest there is minimal 
variation between levels within single ROIs irrespective of 
depth in the block (Figure 3E).
Colorectal cancer tissue microarray
TMA sections were evaluated by RNAscope ISH 
for expression of the medium range control probe PPIB. 
Semi-quantitative microscopic analysis was performed 
by 3 individuals competent in RNAscope analyses (VB, 
SMcQ & LMcI). Results are summarised as a heat map 
for the 353 cases represented in the 4 TMAs analysed 
(Figure 4). The vast majority of cores across the various 
Figure 4: Examples of variation in PPIB expression (0-3) in individual TMA cores in a CRC series. The accompanying 
illustration depicts the range of expression in 4 TMAs. Each TMA is represented by 4 replicate cores from the same donor FFPE block – 
1A, 1B, 1C & 1D. 
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TMAs had either moderate or high numbers of spots in 
tumour cells indicating they had good integrity for test 
probe assessment. In only 2% of cores was absence of 
expression noted and in only 3/353 cases assessed (0.9%) 
was there absence of expression from all 4 cores derived 
from the donor tissue block.
Analysis of PPIB expression by FFPE donor block 
age in years where at least 50 cases were available (2004-
2008) demonstrated that there was no drop off in intensity 
of expression (Figure 5). Cases were as likely to have 
moderate or high levels of PPIB expression when the 
donor block was selected from 2004 as from 2008.
Correlation of PPIB expression to PD-L1 and 
c-MET
Expression of the immune checkpoint biomarker 
PD-L1 and the receptor tyrosine kinase c-MET probes 
were also assessed microscopically in serial sections of 
the CRC TMAs and correlated to the level of expression of 
PPIB. For this analysis 120 cores were selected (40 PPIB 
score 1, 40 PPIB score 2 and 40 PPIB score 3). Expression 
variation is observed for PDL1 (Figure 6A) and C-MET 
(Figure 6B). 
A Kruskal-Wallis test was performed to assess 
differences in PD-L1 and c-MET mean score versus cases 
with PPIB categorical scores 1-3 (Figure 6C & 6D). A 
significant difference was observed between both test 
probes and PPIB scores from 40 cases (p<0.0001). Data 
analysis would suggest that PD-L1 scores of 1, 2 or 3 are 
not affected by the expression of the control PPIB probe. 
However, in cores where no PD-L1 expression is observed 
then caution must be observed when then PPIB score is 
low. Similarly, c-MET RNAscope expressions of >1.5 do 
not appear to be affected by any level of PPIB expression. 
A Chi-Squared test of independence was performed 
Table 1: Summary of the tissues, probes and scoring methodology used. 
Key; Dots per Cell (dpc), Spotstudio Image Analysis (IA), Microscopic Evaluation (M)
Figure 5: PPIB expression in TMA cores in a CRC series by block age of the donor FFPE sample. Almost as many cases 
have moderate or high levels of expression in 2004 as in 2008. The rate of negative cores is actually higher in 2008 but still very low as a 
percentage of total cases. Green – PPIB score of 0; Blue – PPIB score of 1; Red – PPIB score of 2/3.
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to examine the relationship between qualitative spot studio 
image analysis scores generated for c-MET and PPIB. A 
significant interaction was found (X2 (4) = 27.056, p = 
1.937e-05). Based on Pearson residuals of the test statistic, 
a greater than expected association in the number of 
cases with a c-MET and PPIB score of one was observed 
(Figure 7A) (Pearson residuals = 3.5, p < 0.05). Cases 
with a manual PPIB score of 1 were assessed further 
using SpotStudio image analysis for PPIB and c-MET 
expression (Figure 7B). A moderate correlation was 
observed between the 2 probes using Spearman’s Rank. 
(r
s
 = 0.3116, p = 0.0052). This data would indicate that 
in TMA cores with low c-MET scores then caution is 
required in assessment when the PPIB score is also low.
DISCUSSION
The goal of this study was to determine whether 
the suitability of FFPE blocks for mRNA detection could 
be confirmed using RNAscope is situ hybridization 
technology. The analyses performed with 3 RNAscope 
control probes indicate that FFPE tissue samples, collected 
from different tumour types in a prospective biobank 
setting, are fit-for-purpose for in situ hybridization 
analysis with test biomarkers with expression levels 
either comparable with or above that expected from ACD 
recommendations. Analysis of the control probe PPIB at 
different levels of the FFPE blocks demonstrated that there 
was little variation in expression which suggests uniform 
fixation through at least 200 microns of tissue. 
Furthermore we demonstrate that many hundreds of 
colorectal cancer patient FFPE samples acquired from a 
tissue pathology archive and placed in TMA format are 
robust for RNA analysis by RNAscope. These findings 
were most readily confirmed in the malignant epithelial 
cell compartment of the tumours. Correlation of donor 
FFPE block age to PPIB expression in the TMA series 
demonstrated that the RNAscope assay is robust in respect 
of FFPE block storage time. This is a very important 
finding for the ever increasing use of TMAs, derived from 
Figure 6: (A) Varying levels of PD-L1 expression (0-3) in CRC TMA cores. (B) Varying levels of MET expression (0-3) the CRC 
TMA cores. Boxplots depicting the manual scores for PD-L1 (C) and C-MET (D) compared to manual PPIB scores on TMA cores from 40 
cases. A Kruskal-Wallis Test was performed to assess differences in test probe mean score versus cases with PPIB categorical scores 1-3. A 
p value of less than 0.05 was considered statistically significant. 
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donor FFPE blocks from diagnostic or biobank archives, 
in biomarker discovery which because they need to be 
linked to long-term clinical follow up data may be stored 
for long periods of time before TMA construction and 
usage. 
The three control probes used in the study have 
distinct characteristics most of which have been evaluated 
by quantitative gene expression technologies [9-10]. 
POLR2A, which encodes the largest subunit of RNA 
polymerase II, is a low copy, rigorous positive control 
which may be necessary for very low expressing targets. 
It can be an alternative to PPIB for proliferating tissues, 
like tumours, and also for some non-tumour tissues. 
PPIB, which encodes for a cyclosporine-binding protein, 
is the recommended positive control for most tissues 
whereby it is expressed at a sufficiently low level so 
as to provide a rigorous control for sample quality and 
technical performance. PPIB has been shown to be only 
Figure 7: Mosaic plot (A) demonstrating individual contributions of categorical PPIB and c-MET scores with Pearson 
residual base shading. A p value of less than 0.05 was considered significant. Correlation plot (B) demonstrating the relationship of 
digital scores generated for c-MET to PPIB when a manual PPIB score of 1 was given. Correlation was calculated using Spearman’s Rank.
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moderately up-regulated in activated lymphocytes after 96 
hours of gamma-radiation stimulation [11]. Other studies 
have also demonstrated the use of the PPIB probe as a 
reliable and consistent control with little or no background 
in multiple tissue samples [12]. UBC, which encodes for 
a polyubiquitin precursor protein, is a relatively high 
expressing control probe which may not be useful as a 
control for low expressing targets as it can lead to false 
negative results. Similarly, in the context of qRT-PCR the 
question of the correct endogenous control reference genes 
for normalization of data has been the subject of much 
discussion with several studies showing differences in the 
stability of references genes in a variety of tissues [13-16].
While immunohistochemistry is the most widely 
available tissue hybridization technique, it may not be 
suitable in a variety of technical, biological and diagnostic 
frameworks and antibodies require very robust validations 
to show specificity, selectivity and reproducibility [17-18]. 
Indeed the Rimm group have published quite complex 
algorithms for validation of antibodies involving selection 
of best available from vendors followed by testing in cell 
lines, whole-face sections and TMAs. Furthermore, via 
the International Working group for Antibody validations 
(IWGAV), they have proposed a set of guidelines for 
validating antibodies with five conceptual pillars one 
of which must be met as a minimum criterion to claim 
that a particular antibody has been adequately validated 
for a specific application [19]. While some published 
work has attempted to address issues of loss of tissue 
degradation and the effect of increasing cold ischemic 
times on expression levels of protein epitopes via a Tissue 
Quality Index (TQI) this has not progressed beyond proof-
of-concept. Also the concept of TQI is still problematic 
in terms of pre-analytical variables (cold ischaemia, 
hypoxia, penetrative fixation), for choice of epitopes for 
certain biomarkers (phosphorylated proteins and post-
translational modifications) and for different tissue types 
[20-21]. 
Chromogenic RNA hybridization testing, with 
sequence specific probes, may be a robust, specific 
technology which allows for easier validation and 
standardization and is more readily quantified. In situ 
analysis of RNA in single cells at single molecule 
sensitivity in clinical specimens is a valuable tool in the era 
of personalised medicine. There are less validation steps 
in the process and reduced reliance on other strategies to 
prove specificity. It is also important to emphasise that 
due to the almost total absence of background or non-
specific staining, RNA ISH with sequence specific probes 
is less prone to inter-observer variation. Indeed automated 
quantitative RNA in situ hybridization by RNAscope 
has been used to resolve equivocal and/or heterogeneous 
HER2 status in invasive breast carcinoma [22]. In many 
instances such as commercial unavailability of antibodies, 
low abundance, extracellular targets or where the target 
cannot be detected by antibody e.g. secreted proteins then 
mRNA hybridization may be the assay of choice.
Control probe expression in the stromal cell 
populations was much more heterogeneous than in the 
tumour epithelial compartment which indicates that 
much more rigorous and cautious interpretation of test 
biomarkers in these tissue regions is required. This lower 
expression of control probes in stromal tissues may be 
explained in part because, compared to transcriptionally 
active large tumour cells, many stromal cells are resting 
and express very low levels of mRNA [23]. Furthermore 
it is undoubtedly more difficult to assess probe expression 
in stromal cell populations due to the large diversity of 
cell types. 
In the context of single cell profiling to uncover 
events such as transcriptional signalling of c-MET 
associated with early invasive cancer events [7] or with 
potential in the clinical setting of invasive breast cancer 
to detect HER2 [22], the robustness and usefulness of a 
technology such as RNAscope may be hugely beneficial 
but only if underpinned by the use of controls such as 
those described in the present study.
While use of RNAscope to detect mRNAs is 
becoming very popular it should be remembered that 
there is a poor correlation generally reported between 
levels of mRNA and protein. The varied post-translational 
mechanisms involved in turning mRNA in to protein 
are not as yet sufficiently well-defined to calculate 
protein expression levels from mRNA. Also proteins 
differ significantly in their half-life and there may also 
be technical differences in protein vs mRNA detection 
methodologies that limit the ability to correlate between 
protein and mRNA [24].
Both test biomarkers used in this study are known 
to be differentially expressed in the tumour compartment 
of different colorectal cancer cases ranging from absence 
of expression through to high level of expression on 
tumour epithelial cells for PD-L1 [25], or from low to 
high numbers of expressing cells for c-MET [26-27]. 
The present study confirms that the detection of both 
these biomarkers, by RNA in situ hybridization, is robust 
across a large number of samples acquired from a tissue 
pathology archive. Indeed the potential use of sequence 
specific RNA probes to detect PD-L1 expression in the 
clinical tissue pathology setting may be attractive as at 
present there are four PD-L1 assays registered with the 
US Food and Drug Administration which use 4 separate 
PD-L1 antibodies on 2 different automated platforms and 
have different scoring systems [28]. For c-MET analysis in 
CRC there has been discrepant published data which may 
reflect not only differences in technical detection methods 
used (IHC, qRT-PCR, FISH) but also the well-recognised 
problem of the variety of subjective scoring criteria 
that are in use for IHC [29-34]. Is this context c-MET 
RNAscope may offer a realistic alternative for measuring 
c-MET expression in invasive CRC.
In summary our recommendation is firstly do not 
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evaluate cases for test biomarker analysis where control 
probe expression is absent. Secondly, in cases where 
control probe expressions are marginally positive then 
establishment of a cut-off value is required which may 
vary between test biomarkers. Careful analysis of test 
biomarker scores are required to ensure the range of 
differential expression is not intrinsically linked to overall 
mRNA integrity.
MATERIALS AND METHODS
Processing of prospectively collected FFPE 
samples
Prospectively collected colorectal, breast, prostate 
and ovarian tissue FFPE samples were acquired from the 
Northern Ireland Biobank who have ethical approval for 
the collection of surplus tumour and non-tumour control 
tissue (fresh and FFPE) and matched blood samples from 
consented patients within the BHSCT (REC reference 
16/NI/0030). All prospectively collected NIB FFPE 
samples were dissected in a UKAS accredited laboratory, 
processed on Tissue-Tek 6 Vacuum Infiltration Processors 
and embedded in paraffin wax creating FFPE tissue 
blocks. Thin (3µm) tissue sections were cut and stained 
with Haematoxylin and Eosin (H&E) on a Tissue-Tek 
Prisma staining machine. For the present study tissue 
samples with greater than 50% tumour content (proportion 
of the whole tissue that is occupied by tumour tissue) were 
selected for RNAscope.
CRC tissue microarray construction
353 cases of CRC were identified from the FFPE 
tissue pathology archives of the BHSCT. The primary 
collection period of these samples was 2004-2009 with a 
mean storage period of 10 years. Under ethical approval 
from the Northern Ireland Biobank, representative tumour 
blocks were retrieved, and a new section was cut for H&E 
staining for annotation prior to TMA constructions. For 
each selected donor block, four representative areas were 
annotated for targeted coring (3 tumour, 1 stromal/invasive 
edge). TMAs were constructed using a manual tissue 
arrayer (Beecher Instruments, Silver Spring, MD, USA) 
as described previously [8]. The manual arrayer was used 
to extract 1-mm-diameter tissue cores from donor blocks 
for insertion into recipient blocks.
RNAScope in-situ hybridization and image 
analysis
Manual chromogenic RNAScope was performed on 
sections from whole-face and TMA tissue blocks using 
company protocols. Briefly, sections were cut at 4µm, 
air dried overnight, baked at 60C for 1hour, dewaxed and 
air-dried before pre-treatments. For all tissue sections 
a standard pre-treatment protocol was used. Three 
RNAScope positive control probes from Advanced Cell 
Diagnostics (ACD) (3960 Point Eden Way Hayward, CA 
94545) were used in this study: positive control probe 
Homo sapiens ubiquitin C (Hs-UBC) (310041 Accession 
# NM_021009); positive control probe Hs-PPIB (313910 
Accession # NM_000942.4); positive control probe 
HS-POLR2A (310451 Accession NM_000937.4) and 1 
negative control probe to a partial cds; dihydrodipicolinate 
reductase (bacterial DapB: 310043 Accession # 
EF191515). Test probes to the immune pathway associated 
biomarker PDL1 – Hs-CD274 (600861 Accession # 
NM_014143.3 – sequence region 124 - 1122) and the 
receptor tyrosine kinase c-MET Hs-MET (423101 
Accession #NM_000245.2 – sequence region 175-6505) 
were also used to stain the CRC TMAs. Detection of 
specific probe binding sites was with RNAScope 2.5 HD 
Reagent kit – brown from ACD (Cat. No. 322300). 
The numbers and types of tissue samples and 
method of assessment are summarised in Table 1. For 
semi-quantitative microscopical evaluations of control or 
test probe mRNA detection by RNAScope a 4-tier scoring 
system was developed: 0 – negative; 1 = few spots in most 
cells; 2 = moderate number of spots in all cells; 3 = high 
number of spots in all cells 
Image analysis on selected regions of interest 
(ROIs) within the tumour or stromal compartments 
of control probe labelled whole-face sections from 
prospectively collected tissue samples was performed 
using Spotstudio™ Software from ACD with user-
defined thresholds after slides were scanned using an 
Aperio scanner at x40 resolution. Sections were also cut 
and RNAscope performed for PPIB at three different 
levels, separated by 100 microns, through representative 
examples from each of the tumour types. Four comparable 
ROIs at each level were then subject to Spotstudio image 
analysis. Image analysis was also performed to assess 
c-MET mRNA expression against PPIB expression on a 
selected subset of CRC TMA cores.
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